Wellington Management Group LLP Grows Stake in AnaptysBio, Inc. (NASDAQ:ANAB)

Wellington Management Group LLP lifted its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 4.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,939 shares of the biotechnology company’s stock after buying an additional 3,048 shares during the period. Wellington Management Group LLP owned approximately 0.22% of AnaptysBio worth $2,209,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Values First Advisors Inc. purchased a new stake in AnaptysBio during the 3rd quarter worth $49,000. nVerses Capital LLC increased its position in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares during the last quarter. Headlands Technologies LLC increased its position in shares of AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 2,600 shares during the last quarter. Finally, Point72 DIFC Ltd boosted its holdings in AnaptysBio by 680.5% in the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 5,342 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. cut their price target on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Guggenheim decreased their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Truist Financial cut their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday. Finally, Wells Fargo & Company decreased their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.18.

AnaptysBio Price Performance

Shares of ANAB opened at $15.34 on Thursday. The company has a market cap of $466.78 million, a P/E ratio of -2.52 and a beta of -0.11. AnaptysBio, Inc. has a 12 month low of $14.20 and a 12 month high of $41.31. The stock has a fifty day moving average price of $24.59 and a 200 day moving average price of $29.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, research analysts anticipate that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Insider Activity

In related news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 8.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.